News
AIM
0.1380
-12.10%
-0.0190
Weekly Report: what happened at AIM last week (1102-1106)?
Weekly Report · 1d ago
AIM ImmunoTech Inc. Highlights Ampligen Opportunity and 2027 Milestones
NASDAQ · 4d ago
AIM ImmunoTech Furnishes Corporate Presentation on Ampligen Opportunity
TipRanks · 5d ago
AIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027
Benzinga · 5d ago
Weekly Report: what happened at AIM last week (1026-1030)?
Weekly Report · 11/02 09:50
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg
Benzinga · 10/27 12:39
Weekly Report: what happened at AIM last week (1019-1023)?
Weekly Report · 10/26 09:50
Weekly Report: what happened at AIM last week (1012-1016)?
Weekly Report · 10/19 09:50
Weekly Report: what happened at AIM last week (1005-1009)?
Weekly Report · 10/12 09:53
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
Barchart · 10/07 08:14
AIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral Potential
NASDAQ · 10/05 15:53
Weekly Report: what happened at AIM last week (0928-1002)?
Weekly Report · 10/05 09:53
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
Barchart · 10/05 08:22
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Barchart · 09/30 07:44
Weekly Report: what happened at AIM last week (0921-0925)?
Weekly Report · 09/28 09:50
AIM ImmunoTech CEO issues letter to stockholders
TipRanks · 09/22 13:00
Weekly Report: what happened at AIM last week (0914-0918)?
Weekly Report · 09/21 09:50
AIM ImmunoTech Executes Debt-Reducing Equity Exchange Agreements
TipRanks · 09/14 21:39
Weekly Report: what happened at AIM last week (0907-0911)?
Weekly Report · 09/14 09:53
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements
TipRanks · 09/10 21:01
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's flagship product Ampligen is a double-stranded ribonucleic acid (dsRNA) molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The Alferon N Injection (Interferon alfa) is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. It is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant interferons. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS).